Vivek S. Kavadi

Radiation Oncology

1350 First Colony Blvd
Sugar Land, TX 77479

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.

Journal: JCO oncology practice

Published: July 07, 2026

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice.

Journal: International journal of radiation oncology, biology, physics

Published: May 07, 2026

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

Journal: The New England journal of medicine

Published: June 04, 2025

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).

Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).

Journal: International journal of radiation oncology, biology, physics

Published: April 18, 2025

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Long-Term Prospective Outcomes of Intensity Modulated Radiotherapy for Locally Advanced Lung Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Journal: JAMA oncology

Published: June 27, 2024

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 27, 2023

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 27, 2023

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

Journal: Cancer research communications

Published: February 14, 2023

Practice radiation patterns among oncologists in the Oncology Care Model.

Practice radiation patterns among oncologists in the Oncology Care Model.

Journal: The American journal of managed care

Published: October 17, 2022

Radiation Oncology's Place in Payment Reform: ASTRO Advocates for a Place at the Table.

Radiation Oncology's Place in Payment Reform: ASTRO Advocates for a Place at the Table.

Journal: JCO oncology practice

Published: September 15, 2021

A Medicare Claims Analysis of Racial and Ethnic Disparities in the Access to Radiation Therapy Services.

A Medicare Claims Analysis of Racial and Ethnic Disparities in the Access to Radiation Therapy Services.

Journal: Journal of racial and ethnic health disparities

Published: September 01, 2021

Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.

Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617.

Journal: Cancers

Published: July 01, 2021

Showing 1-12 of 23

Last Updated: 09/26/2026